Skip to main content

FOLR1 CAR T-cells

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • RegistryNCT06609928
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRecurrent Childhood Acute Myeloid Leukemia
  • SponsorFred Hutchinson Cancer Center
How FOLR1 CAR T-cells worksNCT066099281 min

What the film says

Read the transcript

One form of leukemia in babies and toddlers is unusually stubborn. It is driven by a fusion of two genes, and only about one child in four is still leukemia-free five years later.

The idea: that fusion switches on a protein healthy blood cells do not make, folate receptor alpha. A target on the cancer and almost nowhere else.

The child's own T cells are fitted with a receptor for it and grown into large numbers. Chemotherapy makes room, then the cells are infused back to hunt the leukemia.

Up to twelve children aged six and under, whose leukemia carries the marker and has come back, at Fred Hutch and Seattle Children's with Katherine Tarlock. First question: safety. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

OUTLINE: This is a dose-escalation study of FH-FOLR1 CAR T. Patients undergo apheresis to obtain T cells for product manufacturing, receive lymphodepleting chemotherapy with fludarabine intravenously (IV) on days -4 to -1, cyclophosphamide IV on days -4 and -3 and receive FH-FOLR1 CAR T IV on day 0.

Patients undergo echocardiography (ECHO) at screening, undergo collection of cerebrospinal fluid (CSF), blood samples and bone marrow aspiration/biopsy throughout the study, and may undergo imaging (such as positron emission tomography (PET) scan). After completion of study treatment, patients are followed up for 15 years.

Chemotherapy drugs, such as fludarabine and cyclophosphamide, are given to a patient before the manufactured FH-FOLR1 CAR T cells are infused back into the patient to assist in the CAR T cell activity in the patient. The trial is evaluating if giving FH-FOLR1 CAR T cell therapy is safe and tolerable for pediatric patients with recurrent or refractory AML.

The study

How the trial runs.

This phase I trial tests the safety, side effects, and best dose of FH-FOLR1 chimeric antigen receptor (CAR) T cells in treating pediatric patients with FOLR1+ acute myeloid leukemia (AML) that has come back after a period of improvement (recurrent) or has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.

T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a FOLR1 on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Subject age ≤ 6 years.
  • Weight ≥ 7 kilograms.
  • AML that expresses FOLR1 by flow cytometry as assessed by Hematologics, Inc.
  • Laboratory and meets one of the below definitions:
  • For subjects who have previously received an allogeneic hematopoietic cell transplantation (HCT), any evidence of AML re-emergence post HCT detectable by flow cytometry.
  • First relapse of AML ≤ 6 months from initial diagnosis.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.